Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C
Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice
New AbbVie hepatitis C combination cures 93 to 97% with genotype 3
Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients
Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation
Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study
Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3
